Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
H. Lasolle, A. A. Schiavo, A. Tourneur, P. Gillotay, B. d. F. da Fonseca, L. Ceolin, O. Monestier, B. Aganahi, L. Chomette, M. M. L. Kizys, L. Haenebalcke, T. Pieters, S. Goossens, J. Haigh, V. Detours, , M. Romitti
This study uses thyroid organoids to show that combining MAPK and PI3K inhibitors can reverse dedifferentiation in Braf-mutated thyroid cancer cells.
bioRxiv · Mar 30, 2023 · PreprintCancer Biology